Basic Information
| LncRNA/CircRNA Name | TSIX |
| Synonyms | NA |
| Region | GRCh38_X:73792205-73829231 |
| Ensemble | ENSG00000270641 |
| Refseq | NR_003255 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | breast cancer |
| ICD-0-3 | C50 |
| Methods | qRT-PCR |
| Sample | BC tissues,blood |
| Expression Pattern | differential expression |
| Function Description | XIST and TSIX were differentially expressed in subtypes of BC patients, and their levels were correlated to PD-L1 expression level. In conclusion, this correlative study has shed light on the role of both lncRNAs XIST and TSIX as potential non-invasive BC immune biomarkers reflecting the evaded immune system of the patient and overcoming the instability problem of common BC biomarkers. |
| Pubmed ID | 31998636 |
| Year | 2020 |
| Title | XIST and TSIX: Novel Cancer Immune Biomarkers in PD-L1-Overexpressing Breast Cancer Patients |
External Links
| Links for TSIX | GenBank HGNC NONCODE |
| Links for breast cancer | OMIM COSMIC |